cas 5190-68-1|| where to buy 4-chloroquinazoline

Product Name:4-chloroquinazoline

IUPAC Name:4-chloroquinazoline

Packing Unit	Available Stock	Price($)
CM114974-5g	in stock	Ǹħ
CM114974-10g	in stock	ŽǎǸ
CM114974-25g	in stock	ǎřĳ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 5190-68-1 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:5190-68-1; Molecular Formula:C8H5ClN2; Melting Point:-; Smiles Code:ClC1=C2C=CC=CC2=NC=N1; Density:

: Catalog Number:CM114974; Molecular Weight:164.59; Boiling Point:281.0±13.0°C at 760 mmHg; MDL No:MFCD00228682; Storage:Keep in inert atmosphere, store at 2-8°C.

: Quinazolines; Quinazolines belong to heterocyclic chemistry, also known as 1,3-naphthalenes. The backbone consists of two six-membered aromatic rings fused to each other, with two nitrogen atoms at positions 1 and 3 on the backbone. The presence of these two nitrogen atoms in quinazoline increases its importance in pharmaceutical and biological reactions. Quinazolines and their derivatives are among the most important heterocyclic compounds due to their diverse chemical reactivity and important range of biological activities.

: Bexotegrast; Pliant announced positive safety and exploratory efficacy data from the INTEGRIS-PSC Phase 2a trial of Bexotegrast (PLN-74809) 320 mg in patients with primary sclerosing cholangitis and suspected liver ibrosis. PLN-74809 is an oral small-molecule dual-selective inhibitor of αvβ6 and αvβ1 integrins for the treatment of IPF and PSC. While present at very low levels in healthy tissues, these integrins are upregulated in the lungs of IPF patients and the bile ducts of PSC patients where they activate TGF-β, a key driver of the fibrotic process. Blocking these integrins is designed to stop TGF-β activation, potentially halting the growth of scar tissue.